GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (MEX:ARGX) » Definitions » Sale Of Investment

argenx SE (MEX:ARGX) Sale Of Investment : MXN0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is argenx SE Sale Of Investment?

argenx SE's sale of investment for the three months ended in Sep. 2024 was MXN0 Mil. It means argenx SE gained MXN0 Mil from selling investments. argenx SE's sale of investment for the trailing twelve months (TTM) ended in Sep. 2024 was MXN0 Mil.

Compared with last quarter (MXN0 Mil in Jun. 2024 ), argenx SE gained the same money from selling investments in Sep. 2024 (MXN0 Mil).

argenx SE Sale Of Investment Historical Data

The historical data trend for argenx SE's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Sale Of Investment Chart

argenx SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 6,800.46 - 25,842.73 26,208.22

argenx SE Quarterly Data
Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

argenx SE Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Sale Of Investment Related Terms

Thank you for viewing the detailed overview of argenx SE's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (MEX:ARGX) » Definitions » Sale Of Investment
Comparable Companies
XBRU:UCB XBRU:TUB XBRU:HYL XBRU:ONWD XBRU:ALIMG XBRU:CYAD XBRU:BIOS XBRU:OXUR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 BNTX BGNE SZSE:300122 ALNY
Traded in Other Exchanges
ARGX:USA ARGXb:UK 0QW0:UK 1AE:Germany A1RG34:Brazil ARGX:Belgium
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Website
https://www.argenx.com
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.